CClinicalTrials.gg
Active, not recruitingNCT03228667Updated Jan 14, 2026

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

A Phase 2 interventional study of N-803 + Pembrolizumab and N-803 + Nivolumab in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Urothelial Carcinoma, sponsored by ImmunityBio, Inc.. Active, not recruiting at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by ImmunityBio, Inc. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study aims to evaluate the safety and efficacy of NAI (nogapendekin alfa inbakicept) in combination with other agents like checkpoint inhibitors and cell therapies across various cancer types and treatment settings. The study includes multiple cohorts based on prior therapies and cancer types, with a focus on assessing overall response rate (ORR), overall survival (OS), and other measures of anti-tumor activity and immune response.

Read the detailed description

All cohorts are closed to enrollment

02

Conditions studied

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Urothelial Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Merkel Cell Carcinoma
  • Melanoma
  • Renal Cell Carcinoma
  • Gastric Cancer
  • Cervical Cancer
  • Hepatocellular Carcinoma
  • Microsatellite Instability
  • Mismatch Repair Deficiency
  • Colorectal Cancer

Keywords

  • Pembrolizumab
  • Nivolumab
  • Non-Small Cell Lung Cancer (NSCLC)
  • Immunotherapy
  • Interleukin-15
  • PD-1 Checkpoint Inhibitor
  • ALT-803
  • Atezolizumab
  • Avelumab
  • Small Cell Lung Cancer (SCLC)
  • Urothelial Carcinoma
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Merkel Cell Carcinoma (MCC)
  • Melanoma
  • Renal Cell Carcinoma (RCC)
  • Gastric Cancer
  • Cervical Cancer
  • Hepatocellular Carcinoma (HCC)
  • Microsatellite Instability-High (MSI-H)
  • PD-L1 Checkpoint Inhibitor
  • Mismatch Repair Deficient (dMMR) Solid Tumor Cancer
  • Colorectal Cancer (CRC)
  • Durvalumab
  • PD-L1 t-haNK
  • N-803
  • Keytruda
  • Opdivo
  • Imfinzi
  • Bavencio
  • Tecentriq
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age ≥ 18 years old.
  2. Able to understand and provide a signed informed consent that fulfills the relevant IRB/IEC guidelines.
  3. Pathologically confirmed stage IV NSCLC disease.
  4. Have received exactly 1 anti-PD-1 or anti-PD-L1 therapy (either pembrolizumab or nivolumab) for advanced disease (stage IV or recurrent disease, or stage I-III disease in certain circumstances) outlined below. Anti-PD-1 or anti-PD-L1 therapy may have been given alone or in combination with other therapy.

    a. For those participants who received neoadjuvant, adjuvant, and/or consolidation anti-PD-1 or anti-PD-L1 therapy for stage

    I-III disease:

    If they had disease progression within (≤) 365 days from initiation (cycle 1 day 1) of anti-PD-1 or anti-PD-L1 therapy, this counts as the single allowed anti-PD-1 or anti-PD-L1 therapy for advanced disease OR if they had disease progression more than (>) 365 days from initiation (cycle 1 day 1) of anti-PD-1 or anti-PD-L1 therapy, this is not considered anti-PD-1 or anti-PD-L1 therapy for advanced disease. These participants must have received anti-PD-1 or anti-PD-L1 therapy for stage IV or recurrent disease.

  5. Have reported disease progression (in the opinion of the treating physician) more than (>) 84 days following initiation (cycle 1 day 1) of their most recent anti-PD-1 or anti-PD-L1 therapy (either pembrolizumab or nivolumab).
  6. Participants who received anti-PD-1 or anti-PD-L1 therapy for stage IV or recurrent disease, must have had a best response of SD, PR or CR (in the opinion of the treating physician) on the anti- PD-1 or anti-PD-L1 therapy (either nivolumab or pembrolizumab) for stage IV or recurrent disease.
  7. Participants with a known sensitizing mutation for which an - approved targeted therapy for NSCLC exists (e.g., EGFR, ALK, ROS1, BRAF, RET, NTRK, KRAS, HER2 and MET sensitizing mutations), must have previously received at least 1 of the approved therapy(s). Prior targeted therapy for participants with targetable alterations is allowed if all other eligibility criteria are also met.
  8. ECOG performance status of 0 to 2.
  9. Measurable tumor lesions according to RECIST v1.1.
  10. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  11. Agreement to practice effective contraception for female participants of child-bearing potential and non-sterile males. Female participants of child-bearing potential must agree to use effective contraception for up 7 months after completion of therapy, and non-sterile male participants must agree to use a condom for up to 7 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), orals, injectables, 2 forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and hormonal therapy.

Exclusion criteria

EXCLUSION CRITERIA (Cohort 6 only)

  1. Systemic autoimmune disease currently requiring treatment (e.g., lupus erythematosus, rheumatoid arthritis, Addison's disease, or autoimmune disease associated with lymphoma). The participant must have been off treatment for 180 days.
  2. History of organ transplant requiring immunosuppression; or history of pneumonitis or interstitial lung disease requiring treatment with systemic steroids; or a history of receiving systemic steroid therapy or any other immunosuppressive medication ≤ 3 days prior to study initiation. Daily steroid replacement therapy (eg, prednisone or hydrocortisone) and corticosteroids used to manage AEs are permitted.
  3. History of known active hepatitis B or C infection.
  4. Active infection requiring antibiotic therapy.
  5. History of or active inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
  6. Had major surgery within 28 days prior to study enrollment. Participants must have fully recovered from the effects of prior surgery in the opinion of the treating Investigator.
  7. Inadequate organ function, evidenced by the following laboratory results:

    1. Absolute lymphocyte count \< institutional ULN.
    2. Absolute neutrophil count (ANC) \< 1,500 cells/mm3.
    3. Platelet count \< 100,000 cells/mm3.
    4. Total bilirubin greater than the upper limit of normal (ULN; unless the participant has documented Gilbert's syndrome).
    5. Aspartate aminotransferase (AST [SGOT]) or ALT (SGPT) > 1.5 × ULN.
    6. Alkaline phosphatase (ALP) levels > 2.5 × ULN.
    7. Hemoglobin \< 9.0 g/dL.
    8. Serum creatinine > 2.0 mg/dL or 177 μmol/L or creatinine clearance \< 40 mL/min (using the Cockcroft-Gault formula below): Female = [(140 - age in years) × weight in kg × 0.85] / [72 × serum creatinine in mg/dL] Male = [(140 - age in years) × weight in kg × 1.00] / [72 × serum creatinine in mg/dL]
  8. Have any of following:

    1. Cirrhosis at a level of Child-Pugh B (or worse);
    2. Cirrhosis (any degree) and a history of hepatic encephalopathy; or
    3. Clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis.
  9. Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to the start of treatment on this study, except for hormone lowering therapy in participants with hormone-sensitive cancer.
  10. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  11. Pregnant and nursing women.
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Cohort 1

    Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor. 1a - Non-small cell lung cancer 1b - Small cell lung cancer 1c - Urothelial carcinoma 1d - Head and neck squamous cell carcinoma 1e - Merkel cell carcinoma 1f - Melanoma 1g - Renal cell carcinoma 1h - Gastric cancer 1i - Cervical cancer 1j - Hepatocellular carcinoma 1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer

    Drug: N-803 + Pembrolizumab · Drug: N-803 + Nivolumab · Drug: N-803 + Atezolizumab · Drug: N-803 + Avelumab · Drug: N-803 + Durvalumab

  • Other
    Cohort 2

    Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.

    Drug: N-803 + Pembrolizumab · Drug: N-803 + Nivolumab

  • Other
    Cohort 3

    Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.

    Drug: N-803 + Pembrolizumab · Drug: N-803 + Nivolumab

  • Experimental
    Cohort 4

    Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.

    Drug: N-803 + Pembrolizumab · Drug: N-803 + Nivolumab · Drug: N-803 + Atezolizumab · Drug: N-803 + Avelumab · Drug: N-803 + Durvalumab

  • Experimental
    Cohort 5

    Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.

    Drug: N-803 + Pembrolizumab + PD-L1 t-haNK · Drug: N-803 + Nivolumab + PD-L1 t-haNK · Drug: N-803 + Atezolizumab + PD-L1 t-haNK · Drug: N-803 + Avelumab + PD-L1 t-haNK · Drug: N-803 + Durvalumab + PD-L1 t-haNK

  • Experimental
    Cohort 6

    Patients who have progressed after an initial response (CR or PR) to a PD-1/PD-L1 checkpoint inhibitor but now exhibit acquired resistance. They have received exactly one line of anti-PD-1 or anti-PD-L1 therapy (either pembrolizumab or nivolumab) for advanced NSCLC (Stage IV or recurrent).

    Drug: N-803 + Docetaxel + Pembrolizumab · Drug: N-803 + Docetaxel + Nivolumab

Interventions

  • DrugN-803 + Pembrolizumab

    Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • DrugN-803 + Nivolumab

    Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • DrugN-803 + Atezolizumab

    Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • DrugN-803 + Avelumab

    Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • DrugN-803 + Durvalumab

    Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • DrugN-803 + Pembrolizumab + PD-L1 t-haNK

    Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • DrugN-803 + Nivolumab + PD-L1 t-haNK

    Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • DrugN-803 + Atezolizumab + PD-L1 t-haNK

    Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • DrugN-803 + Avelumab + PD-L1 t-haNK

    Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • DrugN-803 + Durvalumab + PD-L1 t-haNK

    Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • DrugN-803 + Docetaxel + Pembrolizumab

    The study employs a 6-week cycle combination of: N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and pembrolizumab (200 mg IV).

  • DrugN-803 + Docetaxel + Nivolumab

    The study employs a 6-week cycle combination of:N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and nivolumab (240 mg IV). Nivolumab dosing may be increased to 480mg every four weeks as per the investigator's discretion.

05

What researchers measure

Primary outcomes

  1. ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.

    ORR reflects tumor shrinkage and is the key measure of antitumor activity.

    Time frame: Evaluated from the first dose of study drug and repeated at each scheduled disease-assessment visit for up to 24 months (or until progression/death), with the time-to-response summarized using Kaplan-Meier methods

  2. Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ

    OS is the gold-standard efficacy endpoint; the protocol explores whether an ALC rise predicts a survival benefit.

    Time frame: Measured from the date of the first study-drug administration to the date of death (any cause) and followed for up to 24 months after the last dose (or until death), allowing the correlation with on-treatment ALC changes

Secondary outcomes

  1. ALC response to NAI therapy

    Defined as achieving a mean on-treatment absolute lymphocyte count (ALC) ≥ 1,000 cells/µL.

    Time frame: From the date of first study-drug administration until the earlier of death or the planned end of follow-up, assessed up to 24 months.

  2. Prolongation of therapy

    Measured as the time on NAI treatment, analyzed according to whether the participant attained the ALC response described above.

    Time frame: From the date of first study-drug administration until the earlier of death or the planned end of study follow-up, assessed up to 24 months after the last dose of study drug.

  3. Overall survival (OS) for all patients and subgroups

    Defined as the time from the first study-drug administration to death from any cause.

    Time frame: From the date of first study-drug administration until the earlier of death or the planned end of study follow-up, assessed up to 24 months after the last dose of study drug.

  4. Disease-specific survival (DSS)

    Time from first study drug administration to death resulting from cancer.

    Time frame: From the date of first study-drug administration until the earlier of death or the planned end of study follow-up, assessed up to 24 months after the last dose of study drug.

  5. Progression-free survival (PFS)

    Time from the first study-drug administration to either documented disease progression or death from any cause, whichever occurs first

    Time frame: From the date of first study-drug administration until the earlier of death or the planned end of study follow-up, assessed up to 24 months after the last dose of study drug.

  6. Time to response

    The interval from the first dose of study drug to the first documented objective tumor response (CR or PR)

    Time frame: From the date of first study-drug administration until the earlier of death or the planned end of study follow-up, assessed up to 24 months after the last dose of study drug.

  7. Duration of response (DoR)

    Time from the date of documented response (CR or PR) until disease progression or death.

    Time frame: From the date of first study-drug administration until the earlier of death or the planned end of study follow-up, assessed up to 24 months after the last dose of study drug.

  8. Disease Control Rate (DCR):

    measures the percentage of patients with stable disease (SD), partial response (PR), or complete response (CR). It indicates the proportion of patients who experience benefit from the treatment in terms of disease stabilization or tumor shrinkage.

    Time frame: Assessed at the end of each 6-week cycle (each cycle = 42 days) through 2 years (up to Cycle 17)

  9. Quality of life (QoL) - Assessed in cohorts 1-5 only.

    Assesses patient well-being using standardized questionnaires like EORTC QLQ-C30/LC13 or FACT PRO (module-specific), each with varying scales where higher scores generally indicate better functioning (but may also mean more symptoms).

    Time frame: From the date of first study-drug administration until the earlier of death or the planned end of study follow-up, assessed up to 24 months after the last dose of study drug.

  10. Physical examinations

    A full physical exam is conducted to assess any new or worsening clinical findings.

    Time frame: Baseline (screening), Day 1 (first dose), and prior to every subsequent NAI dose (e.g., every 2 weeks), then at each post-treatment safety visit (Week 12, Week 24, Week 36, Week 48, and at end-of-study visit)

Other outcomes

  1. Incidence of TEAEs and SAEs

    All treatment-emergent adverse events and serious adverse events are recorded and graded using the NCI Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Captured continuously from the first dose of study drug and monitored at every study visit throughout the treatment period and the post-treatment follow-up phase (until study closure, typically up to ~24 months after the last dose).

  2. Laboratory tests

    Routine hematology, chemistry, and other safety-related labs are performed to detect treatment-related abnormalities.

    Time frame: Baseline, Day 1, on-treatment (prior to each dose; every 2 weeks), and at each post-treatment safety visit (Week 12, Week 24, Week 36, Week 48, and end-of-study)

  3. Vital signs

    Blood pressure, heart rate, respiratory rate, temperature, and weight are recorded.

    Time frame: Baseline, Day 1, before each NAI infusion (typically every 2 weeks), and at all scheduled safety follow-up visits (Week 12, Week 24, Week 36, Week 48, and final study visit)

  4. ORR (Objective Response Rate)

    Cohorts 1-5 (irRECIST) Proportion of participants achieving a confirmed complete or partial response per immune-related RECIST.

    Time frame: Assessed from the first dose onward at scheduled tumor-assessment visits (typically every 8-12 weeks) until progression, death, or study end (≈ 24 months).

  5. PFS (Progression-Free Survival)

    Cohorts 1-5 (irRECIST) Time from first dose to disease progression (per irRECIST) or death from any cause, whichever occurs first.

    Time frame: From Day 1 of first study-drug administration to first documented disease progression (per irRECIST/iRECIST) or death from any cause, whichever occurs first, assessed up to 24 months.

  6. Time to response

    Cohorts 1-5 (irRECIST) Interval from first dose to the first documented objective response (CR or PR)

    Time frame: From Day 1 of first study-drug administration to the date of first confirmed complete or partial response, assessed up to 24 months.

  7. DCR (Disease-Control Rate)

    Cohorts 1-5 (irRECIST) Proportion of participants achieving CR, PR, or stable disease per irRECIST.

    Time frame: Assessed at each tumor-assessment visit (baseline, Week 8 ± 1, Week 16 ± 2, Week 24 ± 2, and thereafter every 12 weeks) through 24 months.

  8. DoR (Duration of Response)

    Cohorts 1-5 (irRECIST) Time from first documented response to disease progression or death.

    Time frame: From the date of first confirmed response to subsequent disease progression or death, whichever occurs first, assessed up to 24 months.

  9. Immunogenicity profile

    Cohorts 1-5 (irRECIST) Detection of anti-drug antibodies or other immune responses to the investigational agents.

    Time frame: Blood sampled at baseline, Day 1, Week 4, Week 12, and then every 12 weeks up to 24 months.

  10. Cmax - Maximum plasma concentration of the investigational agent

    The highest observed plasma concentration of the study drug after a single intravenous infusion, expressed in ng · mL-¹. Concentrations are measured using a validated LC-MS/MS assay (lower limit of quantitation = 1 ng · mL-¹).

    Time frame: Assessed on Cycle 1 Day 1 (each cycle = 28 days) and Cycle 2 Day 1. Sampling schedule on each study day: pre-dose, end-of-infusion, 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours post-dose

  11. Tmax - Time to maximum plasma concentration of the investigational agent

    Time elapsed from the start of the infusion to the occurrence of Cmax, expressed in hours. Determined from the same plasma-sampling schedule used for Cmax.

    Time frame: Assessed on Cycle 1 Day 1 (each cycle = 28 days) and Cycle 2 Day 1. Sampling schedule on each study day: pre-dose, end-of-infusion, 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours post-dose

  12. AUC₀-t - Exposure (area under the plasma-concentration-time curve) from time 0 to the last quantifiable concentration

    Calculated using the linear-trapezoidal method applied to the concentration-time data obtained from the intensive sampling schedule (pre-dose through 24 h) on Cycle 1 Day 1. Units are ng · h · mL-¹.

    Time frame: Assessed on Cycle 1 Day 1 (each cycle = 28 days) and Cycle 2 Day 1. Sampling schedule on each study day: pre-dose, end-of-infusion, 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours post-dose

  13. AUC₀-τ - Steady-state exposure over one dosing interval

    Area under the plasma-concentration-time curve over a full dosing interval (τ) at steady state, calculated by the linear-trapezoidal method using pre-dose and post-dose samples collected on Cycle 2 Day 1 (or the first cycle where steady state is confirmed). Units: ng · h · mL-¹.

    Time frame: Assessed on Cycle 2 Day 1 (each cycle = 42 days). Intensive sampling: pre-dose, end-of-infusion, 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours post-dose. Sparse samples at weeks 12, 24, 36, 48, 60, 72, 84 (up to 24 months).

  14. t½ - Terminal elimination half-life of the investigational agent

    The time required for the plasma concentration to decline by 50 % during the terminal phase, calculated by log-linear regression of the last ≥3 measurable concentrations from the intensive sampling (typically 4 h, 8 h, 24 h) on Cycle 1 Day 1. Reported in hours.

    Time frame: Determined from the same Cycle 1 Day 1 intensive sampling. No additional time points are required; the parameter is reported once per participant. The overall data-collection window for the participant is up to 24 months from first dose

  15. ORR (Objective Response Rate)

    Cohort 6 (iRECIST) Proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) as assessed by the investigator using iRECIST criteria.

    Time frame: Assessed from the first study-drug administration onward at scheduled tumor-assessment visits (typically every 8-12 weeks) and reported at the end of the follow-up period (up to the study's planned closure, e.g., ~24 months).

  16. PFS (Progression-Free Survival)

    Cohort 6 (iRECIST) Time from the first dose of study drug to the first occurrence of disease progression (per iRECIST) or death from any cause, whichever comes first.

    Time frame: From Day 1 of first study-drug administration to first documented disease progression (per irRECIST/iRECIST) or death from any cause, whichever occurs first, assessed up to 24 months.

  17. Time to response

    Cohort 6 (iRECIST) - Interval between the first study-drug administration and the date of the first documented objective response (CR or PR) per iRECIST.

    Time frame: From Day 1 of first study-drug administration to the date of first confirmed complete or partial response, assessed up to 24 months

  18. DCR (Disease-Control Rate)

    Cohort 6 (iRECIST) - Proportion of participants who achieve CR, PR, or stable disease (SD) according to iRECIST.

    Time frame: Assessed at each tumor-assessment visit (baseline, Week 8 ± 1, Week 16 ± 2, Week 24 ± 2, and thereafter every 12 weeks) through 24 months

  19. DoR (Duration of Response)

    Cohort 6 (iRECIST) Time from the date of the first documented response (CR or PR) until disease progression (per iRECIST) or death, whichever occurs first.

    Time frame: From the date of first confirmed response to subsequent disease progression or death, whichever occurs first, assessed up to 24 months.

06

Study locations

35 sites
  • Alaska Clinical Research Center
    Anchorage, Alaska 99530, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Chan Soon-Shiong Institute for Medicine
    El Segundo, California 90245, United States
  • MemorialCare Health System
    Fountain Valley, California 37846, United States
  • Glendale Adventist Medical Center
    Glendale, California 91206, United States
  • University of Southern California Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Desert Hematology Oncology Medical Group, Inc.
    Rancho Mirage, California 92270, United States
  • Memorial Healthcare System
    Hollywood, Florida 33021, United States
  • Miami Cancer Institute (Baptist Health South Florida)
    Miami, Florida 33176, United States
  • University of Miami
    Miami, Florida 33180, United States
  • Horizon Oncology Associates
    Lafayette, Indiana 47905, United States
  • University of Iowa Holden Comprehensive Cancer Center
    Iowa City, Iowa 52242, United States
  • Baptist Health - Lexington
    Lexington, Kentucky 40503, United States
  • Baptist Health- Louisville
    Louisville, Kentucky 40207, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • University of Minnesota - Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Mercy Research Joplin
    Joplin, Missouri 64804, United States
  • Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center
    Springfield, Missouri 65804, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • St. Vincent Frontier Cancer Center (SCL)
    Billings, Montana 59102, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Cleveland Clinic - Main Site
    Cleveland, Ohio 44195, United States
  • Mercy Clinic Oklahoma City
    Oklahoma City, Oklahoma 73120, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Gettysburg/Hanover Cancer Centers
    Gettysburg, Pennsylvania 17325, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • St. Francis Cancer Center/Bon Secours St. Francis Health System
    Greenville, South Carolina 29607, United States
  • Spartanburg Medical Center
    Spartanburg, South Carolina 29303, United States
  • Sanford Clinical Research
    Sioux Falls, South Dakota 57104, United States
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
  • Oncology Consultants of Houston
    Houston, Texas 77024, United States
  • Bon Secours Richmond
    Richmond, Virginia 23114, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03228667
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Jul 25, 2017
Start date
Dec 11, 2018
Primary completion
Aug 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jan 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion